18.34
+1.08(+6.26%)
Currency In USD
| Previous Close | 17.26 |
| Open | 17.51 |
| Day High | 18.39 |
| Day Low | 17.16 |
| 52-Week High | 21.71 |
| 52-Week Low | 3.42 |
| Volume | 1.2M |
| Average Volume | 1.22M |
| Market Cap | 848.48M |
| PE | -5.99 |
| EPS | -3.06 |
| Moving Average 50 Days | 18.85 |
| Moving Average 200 Days | 12.61 |
| Change | 1.08 |
If you invested $1000 in UroGen Pharma Ltd. (URGN) since IPO date, it would be worth $1,311.87 as of September 29, 2025 at a share price of $18.34. Whereas If you bought $1000 worth of UroGen Pharma Ltd. (URGN) shares 5 years ago, it would be worth $949.28 as of September 29, 2025 at a share price of $18.34.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Sep 08, 2025 12:00 PM GMT
PRINCETON, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of ind
UroGen Pharma to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
Aug 21, 2025 12:00 PM GMT
PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will parti
UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
GlobeNewswire Inc.
Aug 05, 2025 12:00 PM GMT
24-month Duration of Response (DOR) of 72.2% by Kaplan-Meier estimate was attained in patients who achieved a complete response (CR) at three months (79.6%) PRINCETON, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a bi